Uloric Litigation Attorneys | Information on Uloric and the Increased Risk of Cardiovascular Death
Uloric (febuxostat) is a xanthine oxidase inhibitor prescribed for the chronic management of hyperuricemia, elevated uric acid levels, in adult patients with gout. Gout, which affects more than 8 million Americans, is a painful and persistent form of inflammatory arthritis that develops due to high levels of uric acid in the blood. Takeda Pharmaceuticals, the drug manufacturer of Uloric, brought the drug to market and it originally received FDA approval on February 13, 2009.
In 2009, as part of the Food and Drug Administration’s approval, the FDA required that Takeda was to conduct a mandatory post-marketing cardiovascular safety study. On March 12, 2018, the New England Journal of Medicine published the results of the 6,000 patient safety trial. Patients who took Uloric were found to have a statistically significant increased risk of cardiovascular death compared to those who took Allopurinol, an alternative gout medication.
As of February 2019, the FDA requires that the label of Uloric now has the agency’s strictest and most severe warning, a black box warning.
Patients taking Uloric are at an especially high risk of cardiovascular issues:
They should be aware of the symptoms that may indicate an issue. And, if they experience one or more of the symptoms listed below, they should contact their doctor immediately.
-Rapid or irregular heartbeat
-Difficulty breathing, talking or forming sentences
-Numbness or immobility affecting one side of the body
-Swelling in the legs, ankles and feet
-Fatigue and weakness
If you or a loved one has had cardiovascular issues after having taken Uloric for gout, please reach out to us immediately for a free case evaluation. Call 855-566-3752 or contact us online.